As more evidence emerges about long-term clinical impacts of Covid-19 and long Covid, insurers will need to consider the implications for medical underwriting.

Article

Analysis of insurers’ Solvency and Financial Condition Reports

19 July 2022 - by Joanne Buckle, Natasha Singhal

UK health insurers had strong positions at year-end 2021, with a weighted average SCR coverage ratio of 177%, though down from 198% a year earlier.

Article

Approaches to measuring climate change impacts for medical insurers

31 May 2022 - by Joanne Buckle, Alexander Krauskopf, Natasha Singhal

Using historical data in the U.K. and Germany to help medical insurers better understand the morbidity and mortality risks from climate change

Article

Analysis of insurers’ Solvency and Financial Condition Reports: UK domestic medical insurers and IPMI markets

12 October 2021 - by Joanne Buckle, Natasha Singhal

UK health insurers showed strong positions at year-end 2020, with a weighted average SCR coverage ratio of 198%, versus 178% in 2019.

Article

Peer review: Performance metrics for premier specialist consultants relative to non-premier consultants

14 June 2021 - by Joanne Buckle, Tanya Hayward, Natasha Singhal

A new form of measurement: Does the frequency of change of original consultant measure performance for Vitality Health?

Article

Climate change ORSA guide: Capturing climate change in the ORSA

17 February 2021 - by Ian Penfold, Natasha Singhal, Sophie Smyth

In this paper, we discuss how insurance companies can consider the impact of climate change through their Own Risk and Solvency Assessment (ORSA).

Article

Actuarial benchmarking of inpatient admissions within England using international comparators

17 February 2021 - by Joanne Buckle, Natasha Singhal

England benchmarking of inpatient admissions identifies value opportunities.

Article

How is the English NHS prescription drugs budget spent? Third edition: FY 2019/20

27 January 2021 - by Joanne Buckle, Natasha Singhal, Kishan Desai

This report provides an updated view of National Health Service England prescription drug expenditure for FY 2019/20.